Mineralys Therapeutics, Inc. Common Stock Cash Flow
Concept
Operating Cash Flow
Net Income
Depreciation & Amortization
Stock based compensation
Other non cash items
Change in working capital
Investing Cash Flow
Capital Expenditures
Financing Cash Flow
Dividends Paid
Payout Ratio
Share Issuance / Repurchase
Debt Issued / Paid
Other Investing Activities
End Cash Position
Changes in Cash
Beginning Cash Position
Free Cash Flow
2023
2022
2021
2020
-81M
-72M
0M
5M
-7M
-7M
-102M
0M
203M
0M
-0 %
0M
0M
0M
49M
-38M
88M
-81M
-29M
-30M
0M
0M
-1M
1M
-22M
0M
128M
0M
-0 %
-2M
0M
2M
88M
77M
11M
-29M
-15M
-19M
0M
0M
1M
4M
-22M
0M
24M
0M
-0 %
0M
0M
-2M
11M
9M
1M
-15M
-2M
-3M
0M
0M
0M
0M
-22M
0M
4M
4M
-111.43 %
0M
4M
12M
1M
1M
0M
-2M
Concept
Operating Cash Flow
Net Income
Depreciation & Amortization
Stock based compensation
Other non cash items
Change in working capital
Investing Cash Flow
Capital Expenditures
Financing Cash Flow
Dividends Paid
Payout Ratio
Share Issuance / Repurchase
Debt Issued / Paid
Other Investing Activities
End Cash Position
Changes in Cash
Beginning Cash Position
Free Cash Flow
4Q2023
3Q2023
2Q2023
1Q2023
4Q2022
3Q2022
2Q2022
1Q2022
4Q2021
-29M
-24M
0M
1M
-2M
-4M
-8M
0M
0M
0M
-0 %
0M
0M
-8M
49M
-37M
86M
-29M
-19M
-23M
0M
2M
-2M
4M
4M
0M
0M
0M
-0 %
0M
0M
4M
86M
-15M
101M
-19M
-20M
-12M
0M
1M
-2M
-8M
-16M
0M
-1M
0M
-0 %
0M
0M
-16M
101M
-37M
138M
-20M
-13M
-13M
0M
1M
-1M
0M
-140M
0M
204M
0M
-0 %
0M
0M
-140M
138M
51M
88M
-13M
-10M
-9M
0M
0M
0M
-1M
50M
0M
-1M
0M
-0 %
0M
0M
-1M
88M
39M
49M
-10M
-7M
-7M
0M
0M
0M
0M
-72M
0M
-1M
0M
-0 %
0M
0M
-72M
49M
-79M
128M
-7M
-5M
-6M
0M
0M
0M
1M
50M
0M
118M
0M
-0 %
0M
0M
-1M
128M
112M
16M
-5M
-7M
-8M
0M
0M
0M
1M
0M
0M
12M
0M
-0 %
0M
0M
0M
16M
5M
11M
-7M
-5M
-7M
0M
0M
0M
2M
0M
0M
0M
0M
-0 %
0M
0M
0M
11M
-5M
16M
-5M